Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This study is a 24-week multicenter, randomized, double-blind control trial with
ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary
objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day
to that of 150mg/day and the safety of UDCA treatment.